Abstract
While a number of agents directed at chemokine receptors have entered clinic trials, the vast majority of these have failed, and the enthusiasm for this class of drugs has been attenuated. To date, there are two drugs that inhibit chemokine receptors approved by the FDA. The first to be approved in 2007 was maraviroc (brand name Selzentry, or Celsentri outside the US) which targets CCR5 and is used for the treatment of HIV infection. The second is plerixafor (Mozobil) which was approved in 2008, targets CXCR4, and is used for the mobilization of hematopoietic stem cells. This review will focus on the CC chemokine receptors CCR1 and CCR5. These G protein coupled receptors are both activated by a relatively large number of chemokines, most of which overlap. While most of the drugs for CCR1 have been assessed in the context of autoimmune diseases like multiple sclerosis and rheumatoid arthritis, and those for CCR5 were examined for HIV-infection, we review the role of these receptors in relation to cancer. Recently introduced pharmacophores that serve as agonists or antagonists for the receptors are presented. Efforts to exploit polypharmacology approaches using promiscuous compounds that target more than one receptor are also considered.
Keywords: Cancer, CCL3, CCL5, CCR1, CCR5, chemokine receptor, G protein, G protein coupled receptor, metastasis, polypharmacology.
Current Topics in Medicinal Chemistry
Title:Pharmacological Intervention at CCR1 and CCR5 as an Approach for Cancer: Help or Hindrance
Volume: 14 Issue: 13
Author(s): Angela Karash, Maria R. Mazzoni and Annette Gilchrist
Affiliation:
Keywords: Cancer, CCL3, CCL5, CCR1, CCR5, chemokine receptor, G protein, G protein coupled receptor, metastasis, polypharmacology.
Abstract: While a number of agents directed at chemokine receptors have entered clinic trials, the vast majority of these have failed, and the enthusiasm for this class of drugs has been attenuated. To date, there are two drugs that inhibit chemokine receptors approved by the FDA. The first to be approved in 2007 was maraviroc (brand name Selzentry, or Celsentri outside the US) which targets CCR5 and is used for the treatment of HIV infection. The second is plerixafor (Mozobil) which was approved in 2008, targets CXCR4, and is used for the mobilization of hematopoietic stem cells. This review will focus on the CC chemokine receptors CCR1 and CCR5. These G protein coupled receptors are both activated by a relatively large number of chemokines, most of which overlap. While most of the drugs for CCR1 have been assessed in the context of autoimmune diseases like multiple sclerosis and rheumatoid arthritis, and those for CCR5 were examined for HIV-infection, we review the role of these receptors in relation to cancer. Recently introduced pharmacophores that serve as agonists or antagonists for the receptors are presented. Efforts to exploit polypharmacology approaches using promiscuous compounds that target more than one receptor are also considered.
Export Options
About this article
Cite this article as:
Karash Angela, Mazzoni R. Maria and Gilchrist Annette, Pharmacological Intervention at CCR1 and CCR5 as an Approach for Cancer: Help or Hindrance, Current Topics in Medicinal Chemistry 2014; 14 (13) . https://dx.doi.org/10.2174/1568026614666140827144440
DOI https://dx.doi.org/10.2174/1568026614666140827144440 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
COVID-19: Epidemiology, Pathology, Diagnosis, Treatment, and Impact
Current Pharmaceutical Design Proteins Structures in Leishmania Amastigotes for Clinical Remission of Psoriasis
Current Proteomics In Vivo Tumor Secretion Probing Via Ultrafiltration and Tissue Chamber:Implication for Anti-Cancer Drugs Targeting Secretome
Recent Patents on Anti-Cancer Drug Discovery HIV-Antigens Charged on Phosphorus Dendrimers as Tools for Tolerogenic Dendritic Cells-Based Immunotherapy
Current Medicinal Chemistry NF-κB Signaling: Multiple Angles to Target OA
Current Drug Targets Active Metabolites Resulting from Decarboxylation, Reduction and Ester Hydrolysis of Parent Drugs
Current Drug Metabolism Modulation of MMPs by Cell Surface Integrin Receptor α5β1
Anti-Cancer Agents in Medicinal Chemistry Atherogenesis in Renal Patients: A Model of Vascular Disease?
Current Vascular Pharmacology Rheumatoid Arthritis: A Clinical Overview of New Diagnostic and Treatment Approaches
Current Topics in Medicinal Chemistry RAS/RAF/MEK Inhibitors in Oncology
Current Medicinal Chemistry Mean Platelet Volume: A Link Between Thrombosis and Inflammation?
Current Pharmaceutical Design Current Treatment Strategies for Multiple Sclerosis - Efficacy Versus Neurological Adverse Effects
Current Pharmaceutical Design Signal Transduction by IL-2 and its Receptors as Target in Treatment of Rheumatoid Arthritis
Current Drug Targets - Immune, Endocrine & Metabolic Disorders In vitro And In vivo Immunomodulating Properties of Mesenchymal Stem Cells
Recent Patents on Inflammation & Allergy Drug Discovery RNA Interference-Mediated Validation of Survivin and Apollon/BRUCE as New Therapeutic Targets for Cancer Therapy
Current Topics in Medicinal Chemistry Regulation of Adaptive Immunity by the Neurotransmitter Norepinephrine
Current Immunology Reviews (Discontinued) Neurobiology and Genetics of Behavioural Syndromes of Alzheimers Disease
Current Alzheimer Research New Insights into the Biology of 1-Antitrypsin and its Role in Chronic Obstructive Pulmonary Disease
Current Respiratory Medicine Reviews P Wave Dispersion and Silent Atrial Fibrillation in Cryptogenic Stroke: The Pathogenic Role of Inflammation
Cardiovascular & Hematological Disorders-Drug Targets The Idiopathic Interstitial Pneumonias and Connective Tissue Disease-Associated Interstitial Lung Disease
Current Rheumatology Reviews